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Abstract
 
Background.
 
Neuroblastoma is a childhood
tumor derived from cells of the neural crest, with a widely
variable outcome. Differences in the behavior and prog-
nosis of the tumor suggest that neuroblastoma can be di-
vided into several biologic subgroups. We evaluated the
most frequent genetic abnormalities in neuroblastoma to
determine their prognostic value.
 
Methods.
 
We used Southern blot analysis to study
the allelic loss of chromosomes 1p, 4p, 11q, and 14q, the
duplication of chromosome 17q, and the amplification of
the N-
 
myc 
 
oncogene in 89 neuroblastomas. We also de-
termined the nuclear DNA content of the tumor cells.
 
Results.
 
Allelic loss of chromosome 1p, N-
 
myc 
 
ampli-
fication, and extra copies of chromosome 17q were sig-
nificantly associated with unfavorable outcomes. In a
multivariate analysis, loss of chromosome 1p was the
most powerful prognostic factor. It provided strong prog-
nostic information when it was included in multivariate
models containing the prognostic factors of age and
stage or serum ferritin level and stage. Among the patients
with stage I, II, or IVS disease, the mean (
 

 
SD) three-year
event-free survival was 100 percent in those without al-
lelic loss of chromosome 1p and 34
 

 
15
 
 
 
percent in those
with such loss; the rates of three-year event-free survival
among the patients with stage III and stage IV disease
were 53
 

 
10 percent and 0 percent, respectively.
 
Conclusions.
 
The loss of chromosome 1p is a strong
prognostic factor in patients with neuroblastoma, inde-
pendently of age and stage. It reliably identifies patients
at high risk in stages I, II, and IVS, which are otherwise
clinically favorable. More intensive therapy may be con-
sidered in these patients. Patients in stages III and IV
with allelic loss of chromosome 1p have a very poor out-
look, whereas those without such loss are at moderate
risk. (N Engl J Med 1996;334:225-30.)
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EUROBLASTOMA is a childhood cancer that
originates in cells of the neural crest. The clinical
course of the disease varies widely.
 
1
 
 Patients with lo-
calized neuroblastoma (those in stages I and II) have
a good prognosis after surgical resection, whereas the
majority of patients with stage III or IV neuroblasto-
ma have an adverse outcome despite intensive multi-
modal therapy. However, disseminated stage IVS neu-
roblastomas (those that would be classified as stage
I or II but for the presence of remote disease confined
to the liver, skin, bone marrow, or a combination of
these, without radiographically detectable bone me-
tastases) frequently undergo spontaneous regression.
Factors such as age, tumor stage, tumor histology, and
serum levels of lactate dehydrogenase (LDH) and fer-
ritin are clinically meaningful but imperfect predic-
tors of outcome.
 
2-6
 
 Some patients in stages I, II, and
IVS die from progressive disease, for example, where-
as a minority of those in stages III and IV can be
cured. 
Several nonrandom genetic abnormalities have been
identified in patients with neuroblastoma. These include
allelic loss of chromosomes 1p,
 
7-10
 
 4p (unpublished da-
ta), 11q,
 
11
 
 and 14q,
 
7,11,12
 
 indicating loss of function of as
yet unknown tumor-suppressor genes contained in those
regions. Furthermore, there may be amplification of the
N-
 
myc
 
 oncogene
 
13-15 
 
and additional copies of part of the
long arm of chromosome 17 (17q).
 
16,17
 
 It has been estab-
lished that amplification of the N-
 
myc
 
 oncogene has a
strongly unfavorable prognostic value.
 
14,15
 
 A nearly dip-
loid nuclear DNA content has also been shown to corre-
late with a poor response to chemotherapy and an unfa-
vorable outcome, especially in patients under the age of
two years at diagnosis.
 
15-18
 
 In some series, allelic loss of
chromosome 1p
 
7,9,19,20
 
 has been associated with a poor
outcome, but these results are based on the study of a
limited number of patients. The prognostic value of the
other genetic abnormalities has not yet been studied in
detail. In this study we attempted to estimate the prog-
nostic value of all well-established genetic abnormal-
ities in patients with neuroblastoma.
 
M
 
ETHODS
 
Patients and Collection of Samples
 
We obtained samples of tumor tissue and blood from 101 patients
with neuroblastoma. From 1990 through 1994, 77 samples were col-
lected prospectively from the Emma Kinderziekenhuis–Academic
Medical Center, the Center of Pediatric Oncology of the Southeastern
Netherlands, and the Sophia Kinderziekenhuis (all in the Nether-
lands) and the University Hospital of Ghent (in Belgium). The study
methods were approved by the institutional review board. The tumor
samples were snap-frozen in the operating room and stored at
 

 
80
 
°
 
C. A further 24 tumor and control samples from the years 1984
through 1990 were obtained retrospectively from the tissue bank of
the Emma Kinderziekenhuis–Academic Medical Center. The sam-
ples from eight patients were excluded, because less than 60 percent
of the tumor cells they contained were histologically recognizable.
The status of chromosome 1p could not be assessed in four patients.
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The group of patients described in this paper thus consisted of the
remaining 89 patients.
 
Clinical Characteristics
 
All the patients were classified according to the Evans staging sys-
tem,
 
21
 
 with conventional imaging techniques, metaiodobenzylguani-
dine (MIBG) scanning, and examination of bone marrow aspirates
and biopsy specimens obtained with a trephine. The patients’ ages
at diagnosis were recorded. Serum ferritin and LDH levels at diag-
nosis were determined by routine laboratory procedures, with the
upper limits of the normal range defined as described elsewhere.
 
2-4
 
For the serum ferritin level the upper limit was 142 
 
m
 
g per liter,
 
4
 
 and
for serum LDH it was 1500 U per liter.
 
2,3
 
 The treatment of stage I
and II tumors consisted of surgical resection, followed by chemother-
apy only if there was gross residual disease. Stage III and IV tumors
were treated with various chemotherapeutic regimens, all of which
contained at least an alkylating agent, a platinum derivative, and
vinca alkaloids. From 1990 onward, MIBG labeled with iodine-131
was used in the first-line treatment of unresectable stage III or IV
tumors. Patients with stage IVS tumors were treated only if they had
life-threatening symptoms or when there were signs of tumor pro-
gression.
 
Genetic Analysis
 
Extraction of high-molecular-weight DNA, digestion with appro-
priate endonucleases, Southern blot analysis, and hybridization with
DNA probes were performed as described elsewhere.
 
8
 
 The number
of copies of N-
 
myc
 
 per haploid genome was determined by densito-
metric analysis of filters hybridized with a probe for exon 2 of N-
 
myc
 
(pNb1)
 
13
 
 and a control probe, as described elsewhere.
 
8
 
 In the genetic
analysis of chromosome 1p, we used the following combinations of pol-
ymorphic probes and enzymes: CEB15 and 
 
Taq
 
I at locus D1S172 and
MS1 or MUc1 and
 
 Taq
 
I at locus D1S7. In the analysis of chromosome
4p we used H5.52 and 
 
Msp
 
I at D4S10, p157.9 and 
 
Pst
 
I at D4S111,
pYNZ32 and 
 
Taq
 
I at D4S125, and CEB61 and 
 
Taq
 
I at D4S1100. To
study chromosome 11q we used pMCT28.1 and 
 
Msp
 
I at D11S144 and
SS6 and 
 
Taq
 
I at INT2. To study chromosome 14q we used pAW101
and 
 
Eco
 
RI plus 
 
Taq
 
I at D14S1, pMLJ14 and 
 
Taq
 
I at D14S13, cKKA39
and 
 
Taq
 
I at D14S23, and pAT6.5 and 
 
Ava
 
II plus 
 
Taq
 
I at PI. Loss of an
allele at an informative locus was examined by densitometric analy-
 
*Missing patients and patients who were not able to be eval-
uated for a given characteristic are shown as “not evaluated.”
†By the chi-square test, or by a two-tailed Fisher’s exact test
when one of the values being compared was less than 5.
‡Percentages shown are of all patients who could be evaluat-
ed with respect to the characteristic indicated.
 
Table 1. Clinical Characteristics of 89 Pa-
tients with Neuroblastoma, According to
Chromosome 1p Status.
 
C
 
HARACTERISTIC
 
 
 
AND
 
 
C
 
ATEGORY
 
*
N
 
O
 
 L
 
OSS
OF
 
 1p
(N
 

 
60)
L
 
OSS
 
 
 
OF
 
 1p
(N
 

 
29) P V
 
ALUE
 
†
 
no. of patients (%)
 
‡
 
Stage
I, II, or IVS
III or IV
27 (45)
33 (55)
10 (34)
19 (66)
0.48
Age 
 

 
1 yr
 

 
1 yr
25 (42)
35 (58)
12 (41)
17 (59)
0.84
Ferritin 
 

 
142 
 
m
 
g/liter
 

 
142 
 
m
 
g/liter
Not evaluated
36 (71)
15 (29)
9 
10 (37)
17 (63)
2  
0.008
LDH
 

 
1500 U/liter
 

 
1500 U/liter
Not evaluated
55 (95)
3 (5)
2 
21 (72)
8 (28)
—
0.005
 
*Patients who were not able to be evaluated for a given vari-
able are shown as “not evaluated.”
†By the chi-square test, or by a two-tailed Fisher’s exact test
when one of the values being compared was less than 5.
‡Percentages shown are of all patients who could be evaluated
with respect to the variable indicated.
 
Table 2. Genetic Findings According to Chro-
mosome 1p Status in Samples of Tumor Tis-
sue from 89 Patients with Neuroblastoma.
 
V
 
ARIABLE
 
 
 
AND
 
C
 
ATEGORY
 
*
N
 
O
 
 L
 
OSS
OF
 
 1p
(N
 

 
60)
L
 
OSS
 
 
 
OF
 
 1p
(N
 

 
29)
P 
V
 
ALUE
 
†
 
no. of patients (%)
 
‡
 
Chromosome 4p 
No loss
Loss
Not evaluated
41 (75)
14 (25)
5 
19 (83)
4 (17)
6 
0.63
Chromosome 11q
 
	
 
 
loss
Loss
Not evaluated
31 (79)
8 (21)
21 
15 (79)
4 (21)
10 
0.61
Chromosome 14q
 
	
 
 
loss
Loss
Not evaluated
40 (82)
9 (18)
11
16 (73)
6 (27)
7  
0.53
Chromosome 17q
No gain
Gain
Not evaluated
36 (72)
14 (28)
10 
7 (29)
17 (71)
5 
0.001
N-
 
myc
 
1 copy only
 

 
1 copy
60 (100)
0 
12 (41)
17 (59)
 

 
0.001
Ploidy
Nearly diploid
Aneuploid
Not evaluated
26 (46)
31 (54)
3 
19 (76)
6 (24)
4
0.019
 
sis, as described elsewhere.
 
8
 
 To determine whether additional copies
of the long arm of chromosome 17 were present, we used CMM86
and
 
 Taq
 
I at locus D17S74, THH59 and 
 
Taq
 
I at D17S4, and RMU3
and 
 
Taq
 
I at D17S24, following the same densitometric procedure. We
determined nuclear DNA content by analyzing propidium iodine–
stained suspensions of tumor nuclei, with fluorescence-activated cell
sorting, using a modification of the method of Hedley et al.
 
22
 
Statistical Analysis
 
The statistical end points in our analyses were event-free survival
and overall survival. The events we studied were the recurrence of
disease after the attainment of complete remission and the progres-
sion of disease during therapy. We calculated univariate hazard ratios
with 95 percent confidence intervals, using the Cox proportional-haz-
ards model.
 
23 
 
The simultaneous prognostic effect of various factors
was determined in a multivariate analysis with the Cox proportional-
hazards model.
 
23
 
 The probability of event-free survival was plotted
over time according to specific prognostic factors with Kaplan–Meier
life tables.
 
24
 
 Differences between groups in event-free survival were
tested with log-rank statistics. 
 
R
 
ESULTS
 
Characteristics of the Patients
 
Table 1 shows the clinical characteristics of the 89
patients and the association of these features with the
allelic loss of chromosome 1p. Fifty-two patients (58
percent) had stage III or IV neuroblastoma, and 37 pa-
tients (42 percent) had localized or stage IVS dissemi-
nated tumors. Thirty-seven patients (42 percent) were
less than one year old at diagnosis. Thirty-two of 78 pa-
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tients tested (41 percent) had elevated serum ferritin
levels, and 11 of 87 patients tested (13 percent) had se-
rum LDH levels over 1500 U per liter.
 
Genetic Analysis
 
We used Southern blot analysis to study allelic loss
or gain in several chromosomal regions (i.e., 1p, 4p,
11q, 14q, and 17q) and determine the presence or ab-
sence of N-
 
myc
 
 amplification. The principal findings
and their associations with the allelic loss of chromo-
some 1p are shown in Table 2. Allelic loss of chromo-
some 1p was found in 29 of the 89 patients (33 percent;
an example of such loss is shown in Fig. 1). Allelic loss
of chromosome 1p was independent of the patient’s
age or tumor stage but correlated significantly with
increased serum levels of ferritin or LDH (Table 1).
N-
 
myc
 
 amplification was demonstrated in 17 of the 89
tumor samples (19 percent) (Table 2). All the patients
with N-
 
myc
 
 amplification also had allelic loss of chro-
mosome 1p. Thirty-one of 74 patients for whom there
were data (42 percent) were found to have one or more
additional copies of chromosome 17q. These chromo-
somal gains occurred significantly more often in the
patients with allelic loss of chromosome 1p. There
were allelic losses of chromosome 4p in 18 of 78 pa-
tients for whom data were available (23 percent), of
chromosome 11q in 12 of 58 patients (21 percent), and
of chromosome 14q in 15 of 71 patients (21 percent).
None of these changes were significantly associated
with allelic loss of chromosome 1p or any other genetic
variables studied. Furthermore, allelic loss of chromo-
some 4p, 11q, or 14q and duplication of chromosome
17q were not significantly correlated with age, tumor
stage, or serum level of ferritin or LDH. A nuclear
DNA content in the normal range (i.e., indicating a
nearly diploid tumor) was found in 55 percent of the
tumors studied, and a higher (i.e., aneuploid) DNA
content in 45 percent. Significantly more of the pa-
tients with nearly diploid tumors had N-
 
myc
 
 amplifi-
cation, allelic loss of chromosome 1p, and extra copies
of chromosome 17q. Nearly diploid DNA content was
also found significantly more often in stage III and IV
tumors.
Relation of Clinical and Genetic Factors to Outcome 
We analyzed the ability of the various clinical and
genetic factors to predict clinical outcome. The analy-
ses of event-free survival and overall survival yielded
similar results, reflecting the very small possibility of a
favorable outcome in patients with recurrent neuroblas-
toma. We therefore report the results of the analysis of
event-free survival, because that end point reflects tu-
mor behavior more directly than does overall survival.
The mean period of follow-up for the entire group of
patients was 40 months. 
We calculated univariate hazard ratios with the pro-
portional-hazards model (Table 3). In this analysis, all
four clinical variables studied had significant prognos-
tic value. Among the genetic variables, allelic loss of
chromosome 4p, 11q, or 14q had no prognostic value.
Allelic loss of chromosome 1p and N-myc amplification
were each associated with a high likelihood of an un-
favorable outcome. In addition, extra copies of chro-
mosome 17q and, to a lesser extent, nearly diploid nu-
clear DNA content were each associated with a bad
prognosis.
Multivariate Analysis
Several genetic and clinical factors with significant
prognostic value were interrelated in their ability to
predict clinical outcome (Tables 1 and 2). To identify
the most powerful prognostic factors, we performed
multivariate analyses with the Cox proportional-haz-
ards model. The hazard ratios calculated with two
models using clinical variables are shown in Table 4.
The first model contained age and tumor stage, the
prognostic factors in widest use. The second model
contained tumor stage and serum ferritin level, because
that combination gave the best fit attainable with any
Figure 1. Autoradiographs Showing Allelic Loss of Chromosome
1p in a Neuroblastoma Specimen.
The distribution of alleles at two loci in tumor tissue (T) and nor-
D1S7
T       N
T       N
D1S172
— 19
kb
— 10
— 4.1
kb
— 3.8
mal tissue (N) is shown as detected by a Taq I probe.
*For each variable, the prognostic significance of the first category listed was assessed by
comparing that category with the reference category (the second category listed).
†For the comparison of the hazard ratio shown with a hazard ratio of 1.0 (as postulated by
the null hypothesis).
Table 3. Hazard Ratios Associated with Individual Genetic and
Clinical Prognostic Factors in 89 Patients with Neuroblastoma.
VARIABLE CATEGORIES COMPARED*
HAZARD RATIO 
(95% CONFIDENCE 
INTERVAL) P VALUE†
Clinical factors
Stage
Age 
Ferritin 
LDH 
III or IV vs. I, II, or IVS
1 vs. 1 yr
142 vs. 142 mg/liter
1500 vs. 1500 U/liter
1 copy vs. 1 copy
Loss vs. no loss
Loss vs. no loss
Loss vs. no loss
Loss vs. no loss
Gain vs. no gain
Nearly diploid vs. aneuploid
5.6 (2.3–13.4)
3.7 (1.7–8.0)
6.4 (3.0 – 13.7)
4.6 (2.1–9.9)
0.001
0.001
0.001
0.001
Genetic factors
N-myc 
Chromosome 1p
Chromosome 4p
Chromosome 11q
Chromosome 14q
Chromosome 17q
Ploidy
6.8 (3.5–13.4)
6.7 (3.4–13.3)
0.8 (0.3–2.0)
1.2 (0.5–2.7)
1.1 (0.5–2.4)
3.4 (1.7–6.8)
2.2 (1.1–4.6)
0.001
0.001
0.39
0.98
0.75
0.001
0.031
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combination of the four clinical prognostic factors.
Adding age or serum LDH level to the second model
yielded no additional prognostic information, an indi-
cation that serum ferritin levels correlate with age but
provide more prognostic information.
To test whether including any of the genetic factors
would add prognostic information, we included each
one in both models (data not shown). N-myc status and
chromosome 1p status each contributed significant prog-
nostic information to both models. When we added the
presence of extra copies of chromosome 17q to both
models, we obtained some additional prognostic infor-
mation, but this effect disappeared when either allelic
loss of chromosome 1p or N-myc amplification was sub-
sequently added to the model. Nearly diploid nuclear
DNA content provided no significant prognostic infor-
mation when that factor was added to either model, in-
dicating that the prognostic value it demonstrated on
univariate analysis was redundant with the prognostic
value of the clinical factors.
Superior Prognostic Value of Allelic Loss of 
Chromosome 1p
We performed further multivariate analyses to ex-
plore the prognostic value of the allelic loss of chro-
mosome 1p relative to that of N-myc amplification. The
simultaneous addition of chromosome 1p status and
N-myc status to the second Cox model showed that 1p
status had the strongest predictive power when tested
together with the other three factors (Table 4). When
combined with loss of chromosome 1p, N-myc amplifi-
cation lost its prognostic power. This indicates that
allelic loss of chromosome 1p is superior to N-myc am-
plification as a prognostic factor. Allelic loss of chro-
mosome 1p was found in all patients with N-myc am-
plification, and thus it identified the same patients at
high risk as that factor. However, allelic loss of chro-
mosome 1p was also found in patients with a single
copy of N-myc (i.e., without amplification), and it pre-
dicted their unfavorable outcome. For these patients
the univariate hazard ratio associated with allelic loss
of chromosome 1p was 3.9 (95 percent confidence
interval, 1.6 to 9.6; P0.003), and they had a three-
year rate of event-free survival of 3515 percent.
Among patients with both allelic loss of chromosome
1p and N-myc amplification, the corresponding rate was
0 percent. 
Prognostic Value of Allelic Loss of Chromosome 1p 
Regardless of Age or Tumor Stage
To gain more insight into the effect of allelic loss of
chromosome 1p on clinical outcome we analyzed event-
free survival according to chromosome 1p status among
patients of differing stages and ages. The predicted rate
of event-free survival for three years among patients in
stages I, II, and IVS was 836 percent, as compared
with 307 percent among patients in stages III and IV
(P0.002) (Fig. 2A). Among patients with allelic loss of
chromosome 1p, the rate of event-free survival for three
years was 127 percent, as compared with 756 per-
cent among those in whom no such loss was detectable
(P0.001) (Fig. 2B). Among patients with stage I, II,
or IVS disease, loss of chromosome 1p identified those
in whom standard treatment was most likely to fail
(three-year event-free survival, 3415 percent) (Fig. 2C).
The remaining patients in these disease stages, who did
not have allelic loss of chromosome 1p, all survived for
three years without events (P0.001). Among patients
with stage III or IV disease, loss of chromosome 1p de-
fined a very-high-risk group, none of whose members
survived for three years free of events, whereas among
those who did not have such loss the three-year event-
free survival was 5310 percent (P0.001) (Fig. 2D).
Among the 52 patients one year old or older, none of
the 17 who had 1p loss in their tumors survived without
events for three years, whereas the rate of three-year
event-free survival was 529 percent in the 35 who did
not have 1p loss (P0.001). Among the 37 patients less
than one year old, the three-year event-free survival in
the 12 with allelic loss of 1p was 3215 percent, as
compared with 100 percent in the 25 without such loss
(P0.001).
The group of patients with N-myc amplification was
a subgroup of the patients with 1p loss. Therefore, the
patients without N-myc amplification constituted a group
in which loss of chromosome 1p had additional prog-
nostic value. The clinical characteristics of these two
groups with allelic loss of chromosome 1p differed.
N-myc amplification occurred together with 1p loss main-
ly in patients with stage III or IV disease (16 of 17 pa-
tients) and in patients one year old or older (13 of 17
patients). Among the 72 patients without N-myc ampli-
fication, 12 (17 percent) had allelic loss of chromosome
1p. Three of these 12 patients had stage IV tumors and
*For each variable, the prognostic significance of the first category listed was assessed by
comparing that category with the reference category (the second category listed).
†For the comparison of the hazard ratio shown with a hazard ratio of 1.0 (as postulated by
the null hypothesis).
Table 4. Hazard Ratios Associated with Clinical and Genetic
Prognostic Factors in a Multivariate Analysis of 89 Patients with
Neuroblastoma, Using Cox Proportional-Hazards Models.
VARIABLE AND MODEL CATEGORIES COMPARED*
HAZARD RATIO 
(95% CONFIDENCE 
INTERVAL) P VALUE†
Clinical factors
First model
Stage
Age
III or IV vs. I, II, or IVS
1 vs. 1 yr
4.0 (1.6–10.3)
2.2 (0.9–5.0)
0.003
0.07
Second model
Stage
Ferritin
III or IV vs. I, II, or IVS
142 vs. 142 mg/liter
2.6 (1.0–6.5)
4.9 (2.2–11.0)
0.043
0.001
Genetic factors added
Second model
Stage
Ferritin
N-myc 
Chromosome lp
III or IV vs. I, II, or IVS
142 vs. 142 mg/liter
1 copy vs. 1 copy
Loss vs. no loss
2.6 (1.0–6.9)
2.9 (1.2–6.7)
1.0 (0.4–2.8)
4.4 (1.6–11.8)
0.062
0.015
0.94
0.004
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were one year old or older. The remaining nine patients,
who had 1p loss but no N-myc amplification, had stage
I, II, or IVS neuroblastomas, and eight of these patients
were less than one year old. This shows that among the
patients without N-myc amplification, most of those at
high risk who were identified on the basis of allelic loss
of chromosome 1p were under the age of one year and
had stage I, II, or IVS tumors.
DISCUSSION
Our study found that allelic loss of chromosome 1p
is a powerful prognostic indicator in patients with neu-
roblastoma. Univariate testing showed that four genet-
ic variables (allelic loss of chromosome 1p, N-myc am-
plification, extra copies of chromosome 17q, and a
nearly diploid nuclear DNA content) were significant
predictors of unfavorable outcome. The prognostic val-
ue of N-myc amplification in neuroblastoma is well es-
tablished.14,15 In this study, allelic loss of chromosome 1p
was found to be a better prognostic indicator than N-myc
amplification. The latter was present in a subgroup of
patients whose tumors had allelic loss of chromosome
1p. Moreover, patients whose neuroblastomas had a sin-
gle copy of N-myc and allelic loss of chromosome 1p
were at high risk for an unfavorable outcome. The pres-
ence of extra copies of chromosome 17q and nearly dip-
loid nuclear DNA content were of only minor prognostic
significance as compared with allelic loss of chromo-
some 1p and N-myc amplification. 
The main clinical value of allelic loss of chromosome
1p as a prognostic factor lies in its ability to detect pa-
tients at high risk among those who do not have N-myc
amplification. For patients with stage I, II, or IVS dis-
ease, N-myc amplification was a rare event and was not
Figure 2. Kaplan–Meier Curves for Event-free Survival.
The study population of patients with neuroblastoma is analyzed according to stage in Panel A and according to chromosome 1p
status in Panel B. Patients with stage I, II, or IVS disease are analyzed according to chromosome 1p status in Panel C, and patients
with stage III or IV disease are analyzed according to chromosome 1p status in Panel D. Vertical bars show the 95 percent confidence
intervals for three-year event-free survival, except for the group in Panel D with stage III or IV disease and allelic loss of chromosome
1p, for whom the bar shows two-year survival without events.
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present in the majority of patients with an unfavorable
outcome. Patients with stage I, II, or IVS disease who
had 1p loss (12 percent of the patients in this series)
were at a higher risk for recurrence than those who did
not have such loss (three-year event-free survival, 34
percent vs. 100 percent). In patients such as the former,
more aggressive therapy at diagnosis may be consid-
ered. Patients with stage I, II, or IVS disease without al-
lelic loss of chromosome 1p (30 percent of the patients
in this series) had an excellent prognosis (three-year
event-free survival, 100 percent). In this group of pa-
tients, therapy should be as minimal as possible and
should be viewed in the light of possible late effects.
Among patients in stages III and IV, additional patients
at very high risk who did not have N-myc amplification
were identified on the basis of 1p loss. However, in this
group the additional prognostic value of 1p loss was
limited, because most of the patients at very high risk
had N-myc amplification together with allelic loss of chro-
mosome 1p. The current intensive multimodal therapy
may be especially useful for patients with stage III or IV
disease but no 1p loss, whereas more innovative thera-
peutic approaches may be justified in patients with stage
III and IV disease who have such loss.
The association between allelic loss of 1p and out-
come has been described in three other studies. Fong et
al.7 described five patients without N-myc amplification
who had allelic loss of chromosome 1p, three of whom
remained disease-free for more than three years. Am-
bros et al.20 studied 42 stage I and II neuroblastomas
with single copies of N-myc. Among the 5 patients with
1p loss, 3 had recurrences, as compared with 1 of the
remaining 37 patients without such loss. Takeda et al.9
described four patients with allelic loss of 1p and no
N-myc amplification who had a relatively short mean
follow-up of 15 months and did not have events. In our
series, the 12 patients with allelic loss of chromosome
1p and a single copy of the N-myc gene had a relative
risk of recurrent disease of 3.9, with a three-year event-
free survival of 35 percent. Taken together, these data
indicate that allelic loss of chromosome 1p identifies
more patients who are likely to have an unfavorable
outcome than does N-myc amplification alone. Howev-
er, some patients whose tumors have allelic loss of
chromosome 1p and a single copy of the N-myc gene
are long-term survivors. Thus, the principal advantage
of using allelic loss of chromosome 1p as a prognostic
factor is in identifying high-risk patients among those
with single copies of N-myc, the majority of whom have
stage I, II, or IVS neuroblastomas.
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pens, K. Moorman-Voestermans, Y. Meijer, N. Schouten-van Meeter-
en, and M. van Weel for providing blood and tumor samples; to J.H.
Bras for assistance with the histologic analyses; to A. J.M. de Craen
for assistance with the statistical analysis; and to J. Armour,
A. Frischauf, M. Schwab, G. Vergnaud, the Japanese Cancer Re-
sources Bank, and the American Type Culture Collection for making
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